Single-cell Omics Market - By Product Type (Genomics, Transcriptomics, Proteomics, Metabolomics), Application (Oncology, Cell Biology, Neurology, Immunology), End-user (Pharma & Biotech Companies, Hospital Laboratories), Global Forecast (2023 – 2032)

Single-cell Omics Market - By Product Type (Genomics, Transcriptomics, Proteomics, Metabolomics), Application (Oncology, Cell Biology, Neurology, Immunology), End-user (Pharma & Biotech Companies, Hospital Laboratories), Global Forecast (2023 – 2032)

Single-cell Omics Market Size

Single-cell Omics Market size accounted for USD 2.4 billion in 2022 and is estimated to grow at 20.2% to reach USD 15.5 billion by 2032. The escalating R&D investments in single-cell analysis research and rising funding programs serve as a pivotal growth driver for the market.
 

For instance, in November 2022, the Texas A&M University System has received a USD 1.19 million grant from the National Institutes of Health (NIH) to leverage single-cell sequencing technology. This surge in investment is propelled by the profound potential of single-cell omics technologies to revolutionize drug discovery, development, and personalized medicine. Such increasing investment in single-cell analysis research is anticipated to boost the market progress.
 

The market refers to the segment of the biotechnology and life sciences industry that encompasses the development, production, and commercialization of technologies, tools, products, and services designed to study the molecular characteristics of individual cells at various omics levels.

COVID-19 Impact

The emergence of the COVID-19 pandemic had a positive impact on single-cell omics market. As the world faced an unprecedented health crisis, researchers and scientists turned to single-cell omics technologies as powerful tools to solve the complexities of the SARS-CoV-2 virus and its effects on the human body. These technologies played a pivotal role in characterizing immune responses, identifying biomarkers, and interpreting disease mechanisms, thereby supplemented market trends. Also, single-cell omics enabled the rapid development of targeted antiviral treatments and vaccines by providing insights into the intricate interactions between the virus and host cells. Moreover, the increased attention and funding directed towards COVID-19 research catalysed innovation in single-cell omics platforms, making them more accessible, efficient, and scalable. Such aforementioned factors are anticipated to foster the market expansion.
 

Single-cell Omics Market Trends

The increasing prevalence of cancer will significantly boost the market. For instance, according to the American Cancer Society report, in 2022, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. Similarly, according to the Canadian Cancer Society, 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. As cancer rates continue to rise, traditional treatment approaches face challenges in effectively targeting the heterogeneous nature of tumours. Single-cell omics, with its capability to analyse individual cells within tumours, offers a transformative solution that aligns seamlessly with the demands of precision medicine.
 

Single-cell Omics Industry Restraint

A significant market restraint for the single-cell omics market is the high cost associated with single-cell analysis. While the potential insights and benefits provided by single-cell omics technologies are substantial, the expenses tied to implementing and conducting single-cell analyses can be significant barriers for widespread adoption. The costs encompass various aspects, including acquiring specialized instrumentation, purchasing reagents, maintaining the equipment, and investing in skilled personnel capable of executing complex analyses and data interpretation. These financial considerations can pose challenges for smaller research institutions, academic labs, and startups with limited resource, thereby hampering the market demand.
 

Single-cell Omics Market Analysis

By product type, the single-cell omics market is classified into single-cell genomics, single-cell proteomics, single-cell metabolomics, and single-cell transcriptomics. The single-cell genomics segment accounted for 42.8% of the business share in 2022 and is projected to witness considerable growth over the analysis timeframe. Single-cell genomics allows researchers to explore the genomic composition of individual cells, thereby help in revealing variations that remain hidden in aggregated analyses. Also, this technology provides insights into rare cell types, clonal populations, and subtle genetic mutations that hold crucial implications for various fields, from cancer research to developmental biology. Such associated advantages will supplement the market expansion.
 

Based on application, the single-cell omics market is segmented into oncology, cell biology, neurology, immunology, and other applications. The oncology segment accounted for 54.2% of the revenue share in 2022. The increasing prevalence of cancer, continuous advancements in single-cell analysis methods, and growing utilization of omics-based instruments for investigating cancer advancement are some of the major factors driving the market growth. Also, the continuous progress in metabolomics and the incorporation of single-cell metabolomics into cancer detection due to its heightened ability to detect cancer cells with increased sensitivity is expected to accelerate the market trends. Further, scientists are investigating diverse uses of single-cell technologies in various domains, encompassing genomics, transcriptomics, proteomics, and metabolomics.
 

Based on end-user, the single-cell omics market is segmented into academic and research organizations, pharmaceutical & biotechnology companies, hospital and diagnostic laboratories, and other end-users. The academic and research organizations segment is projected to witness considerable growth of 20% over the analysis timeframe. Increasing efforts from various market players to escalate their single-cell sequencing capabilities is anticipated to supplement the market growth. For instance, in February 2023, Singular Genomics Systems, Inc., launched its Max read kits for single cell applications on the company’s G4 sequencing platform. Such initiatives by market players will propel the market growth. Furthermore, increasing number of research studies conducted by various research institutes to explore a wide range of applications within the field of cellular biology will accelerate the market share.
 

North America single-cell omics market accounted for 47% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. North America has emerged as a hub for scientific innovation and technological advancement, fostering a dynamic environment conducive to the development and adoption of cutting-edge single-cell omics technologies. Moreover, the presence of several market players in the region will propel the market trends. Additionally, the region's strong emphasis on precision medicine and personalized healthcare aligns with the capabilities of single-cell omics, driving its integration into clinical research and diagnostics. Moreover, the availability of funding and strategic investments, coupled with regulatory support for innovation, further propels the growth of the market in North America.
 

Single-cell Omics Market Share

Major market players operating in the single-cell omics market include

• CELLENION
• PerkinElmer Inc.
• 10x Genomics
• ANGLE plc
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Single-cell Omics Industry News

• In April 2023, Fulgent Genetics launched Mission Bio platform to broaden accessibility of single-cell multi-omics for drug development and clinical research. This strategy helped the company to create new opportunities for the expansion of single-cell multi-omics in the field of drug development and research.
   
• In June 2021, SCIENION and Cellenion launched its cellenCHIP 384 for single cell omics sample preparation, introducing it as the integral consumable in the new cellenCHIP 384 – 3’RNA-seq kit for scalable, nanoliter volume library preparation of single cells. This strategy helped the company to expands their portfolio for single cell analytics.
   

The single-cell omics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product Type

• Single-cell genomics
• Single-cell transcriptomics
• Single-cell proteomics
• Single-cell metabolomics

By Application  

• Oncology
• Cell biology
• Neurology
• Immunology
• Other applications

By End-user

• Academic and research organizations
• Pharmaceutical & biotechnology companies
• Hospital and diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa